


a. CompEx


SIROCCO



Number at risk:

Benralizumab	383	325	299	275	260	240	216	209	197	186	182	177	-	-
Placebo	389	302	261	230	204	187	177	160	146	135	128	119	-	-

CALIMA




Number at risk:

Benralizumab	428	376	337	302	281	266	252	239	226	220	212	200	195	183
Placebo	425	345	300	268	242	228	217	205	189	181	172	160	151	141

b. SevEx


SIROCCO



Number at risk:

Benralizumab	383	355	333	314	301	281	260	250	237	224	220	215	-	-
Placebo	389	338	309	280	250	233	221	201	192	181	173	167	-	-

CALIMA




Number at risk:

Benralizumab	428	398	370	344	326	316	301	292	278	267	259	249	244	233
Placebo	425	376	342	315	293	280	270	260	242	233	221	208	196	182

c. AWE


SIROCCO



Number at risk:

Benralizumab	383	339	323	307	298	277	263	258	252	247	242	232	-	-
Placebo	389	334	303	282	269	261	248	233	218	208	200	182	-	-

CALIMA



Number at risk:

Benralizumab	427	393	363	343	329	318	307	297	289	285	280	274	267	246
Placebo	425	375	349	326	306	290	279	269	262	253	247	243	238	224